On October 11, 2022, ICER released its draft evidence report, “Fezolinetant for
Moderate to Severe Vasomotor Symptoms Associated with Menopause.” This
document provides a framework for considering what aspects of ICER’s review are
important to women and their families, and how to consider presenting those
perspectives. This guide specifically provides insights about how to read and respond to
ICER’s draft evidence report, as well as how to request a slot to make comments during
ICER’s public meeting.